Business
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8%
About this update from Repligen Corporation
[{"type":"text","content":"Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13% excluding COVID, overcoming two points of currency headwind. Total orders outpaced sales by 6%, driven by our Filtration and Analytics franchises. The strength we saw in the third quarter for CDMOs and capital equipment continued during the fourth quarter, with sequential revenues increasing approximately 20% and 30% respectively. While we continue to monitor China and emerging biotech, the overall bioprocessing market is returning to growth. Our order momentum during the second half gives us confidence that we can achieve our 2025 guidance.” Q4 2024 BUSINESS HIGHLIGHTS CDMO and capital equipment. Orders accelerated sequentially in the quarter, increasing ~15% and ~30% respectively, confirming both markets are fundamentally improvingM&A. Closed acquisition of chromatography innovator Tantti Laboratory Inc, strengthening and expanding our Protein and Chromatography offering in new modalitiesNew products. Launched AVIPure® dsRNA resin, the industry’s first affinity resin for the removal of double-stranded RNA (dsRNA); a groundbreaking solution targeting mRNA-based therapeutics and vaccinesSustainability. Published our 2023 Sustainability report “Advancing Impacts”, highlighting the company’s progress across numerous environmental, social and governance (ESG) initiatives FINANCIAL PERFORMANCE Q4 and Full Year 2024 financial performance (compared to prior year periods except as noted).All adjusted figures are non-GAAP and, except for earnings per ...